ArticleBJOG : an international journal of obstetrics and gynaecology2021
Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
Article in BJOG : an international journal of obstetrics and gynaecology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of economic evaluations of cervical cancer screening methods.Systematic reviews · 2022Pooled it
- Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial.Cancer medicine · 2021Trial
- Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage.International journal of cancer · 2026Article
- Cost-effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV-positive women in cervical cancer screening.International journal of cancer · 2026Article
- Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis.Lancet regional health. Americas · 2026Article
- Risk-Based Triage Using Cytology and HPV Genotyping to Reduce Unnecessary Colposcopy: A Real-World Cross-Sectional Study.Biomedicines · 2026Article
- Under which realistic circumstances is hrHPV self-sampling increasing cervical screening effectiveness in a partly vaccinated population? A modelling study.International journal of cancer · 2026Article
- Optimization of RNAscope for HPV mRNA detection in liquid-based cervical cytology samples.Frontiers in oncology · 2026Article
- European Code Against Cancer, 5th edition - organised cancer screening programmes.Molecular oncology · 2026Review
- Molecular Screening for Cervical Cancer.Genes · 2025Review
- Optimizing the Harms and Benefits of Cervical Screening in a Partially Vaccinated Population in Ontario, Canada: A Modeling Study.Medical decision making : an international journal of the Society for Medical Decision Making · 2025Article
- Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.BMC medicine · 2025Article
- Molecular Testing as Triage in Cervical Cancer Screening: Economic Evaluation Using Headroom Analysis.Cancers · 2025Article
- Locally-tailored vs. centrally-administered strategies for implementation of primary human papillomavirus (HPV) screening in an integrated healthcare system: a qualitative research study.Frontiers in health services · 2025Article
- Cost-Effectiveness of Computer-Assisted Cytology in a Primary hrHPV-Based Cervical Cancer Screening Programme.Cancer medicine · 2024Article
- Perspective of obstetric care-providers on being involved in cervical cancer screening during antenatal care in the Netherlands.Cancer medicine · 2024Article
- Article
- Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.Ecancermedicalscience · 2024Review
- Impact of health-related behavioral factors on participation in a cervical cancer screening program: the lifelines population-based cohort.BMC public health · 2023Article
- An artificial intelligence based app for skin cancer detection evaluated in a population based setting.NPJ digital medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
objectiveWe aim to compare the cost-effectiveness of the old cytology programme with the new high-risk human papillomavirus (hrHPV) screening programme, using performance indicators from the new Dutch hrHPV screening programme.
designModel-based cost-effectiveness analysis.
settingThe Netherlands. POPULATION: Dutch 30-year-old unvaccinated females followed up lifelong.
methodsWe updated the microsimulation screening analysis (MISCAN) model using the most recent epidemiological and screening data from the Netherlands. We simulated both screening programmes, using the screening behaviour and costs observed in each programme. Sensitivity analyses were performed on screening behaviour, utility losses and discount rates.
main outcome measuresCervical cancer incidence and mortality rates, number of screening tests and repeat tests, colposcopy referrals by lesion grade, costs from a societal perspective, quality-adjusted life years (QALYs) gained and cost-effectiveness.
resultsThe new Dutch cervical cancer screening programme decreased the cervical cancer mortality by 4% and the incidence by 1% compared with the old programme. Colposcopy referrals of women without cervical intra-epithelial neoplasia grade 2 or worse, increased by 172%, but 13% more QALYs were still achieved. Total costs were reduced by 21%, mainly due to fewer screening tests. Per QALY gained, the hrHPV programme cost 46% less (€12,225) than the cytology programme (€22,678), and hrHPV-based screening remained more cost-effective in all sensitivity analyses.
conclusionsThe hrHPV-based screening programme was found to be more effective and cost-effective than the cytology programme. Alternatives for the current triage strategy should be considered to lower the number of unnecessary referrals. TWEETABLE ABSTRACT: First results after implementation confirm that HPV screening is more cost-effective than cytology screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.